Literature DB >> 28596056

Development and initial validation of a sensory threshold examination protocol (STEP) for phenotyping canine pain syndromes.

Sandra Sanchis-Mora1, Yu-Mei Chang2, Siobhan Abeyesinghe3, Amy Fisher4, Holger A Volk5, Ludovic Pelligand6.   

Abstract

OBJECTIVE: To study the feasibility and test-retest repeatability of a sensory threshold examination protocol (STEP) and report the quantitative sensory threshold distributions in healthy dogs. STUDY
DESIGN: Prospective, observational, cohort study. ANIMALS: Twenty-five healthy client-owned dogs.
METHODS: Tactile sensitivity test (TST) (von Frey filaments), mechanical thresholds (MT with 2, 4 and 8 mm probes), heat thresholds (HT) and responsiveness to cold stimulus (CT at 0 °C) were quantitatively assessed for five body areas (BAs; tibias, humeri, neck, thoracolumbar region and abdomen) in a randomized order on three different occasions. Linear mixed model and generalized linear mixed models were used to evaluate the effects of body weight category, age, sex, BA, occasion, feasibility score and investigator experience. Test-retest repeatability was evaluated with the intra-class correlation coefficient.
RESULTS: The STEP lasted 90 minutes without side effects. The BA affected most tests (p ≤ 0.001). Higher thresholds and longer cold latencies were scored in the neck (p ≤ 0.024) compared to other BAs. Weight category affected all thresholds (p ≤ 0.037). Small dogs had lower MT (∼1.4 N mean difference) and HT (1.1 °C mean difference) than other dogs (p ≤ 0.029). Young dogs had higher HT than adults (2.2 °C mean difference) (p = 0.035). Gender also affected TST, MT and HT (p < 0.05) (females versus males: TST odds ratio = 0.5, MT = 1.3 N mean difference, HT = 2.2 °C mean difference). Repeatability was substantial to moderate for all tests, but poor for TST. There was no difference in thresholds between occasions, except for CT. Test-retest repeatability was slightly better with the 2 mm MT probe compared to other diameters and improved with operator experience. CONCLUSIONS AND CLINICAL RELEVANCE: The STEP was feasible, was well tolerated and showed substantial test-retest repeatability in healthy dogs. Further validation is needed in dogs suffering pain.
Copyright © 2017 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia. All rights reserved.

Entities:  

Keywords:  dog; mechanical; nociception; quantitative sensory testing; thermal

Mesh:

Year:  2017        PMID: 28596056     DOI: 10.1016/j.vaa.2016.09.004

Source DB:  PubMed          Journal:  Vet Anaesth Analg        ISSN: 1467-2987            Impact factor:   1.648


  4 in total

1.  Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: An open label clinical trial.

Authors:  Beatriz P Monteiro; Louis-Philippe de Lorimier; Maxim Moreau; Guy Beauchamp; Jeffrey Blair; Bertrand Lussier; Jean-Pierre Pelletier; Eric Troncy
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

2.  Serum artemin is not correlated with sensitivity within dogs with naturally occurring osteoarthritis pain.

Authors:  Ankita Gupta; Ludovica Chiavaccini; Laura M Minnema; King Wa Chiu; David Knazovicky; Jonathan A Hash; Santosh K Mishra; B Duncan X Lascelles
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

3.  Investigation of sensory thresholds in Cavalier King Charles Spaniels with and without Chiari-like malformations and syringomyelia.

Authors:  Courtney R Sparks; Angela Gorney; Kim Williams; Emily H Griffith; Sofia Cerda-Gonzalez; B Duncan X Lascelles; Natasha J Olby
Journal:  J Vet Intern Med       Date:  2018-10-11       Impact factor: 3.333

4.  Evaluation of Quadratus Lumborum Block as Part of an Opioid-Free Anaesthesia for Canine Ovariohysterectomy.

Authors:  Jaime Viscasillas; Sandra Sanchis-Mora; Paula Burillo; Vicente Esteve; Ayla Del Romero; Pilar Lafuente; Jose Ignacio Redondo
Journal:  Animals (Basel)       Date:  2021-12-01       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.